Vertex continues deal streak to add modalities and indications

Vertex continues to use deals to expand beyond its stronghold in small molecules for cystic fibrosis, signing at least 17 agreements for new technologies since the start of 2020, with five of those deals coming this year. Discovery deals for technologies that can edit or deliver genes appears to be the company’s sweet spot. 

A look at the deal-making activity of  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) over the past three years suggests the big biotech is amassing a set of complementary technologies that will enable it to attack Type I diabetes and rare genetic disorders in multiple ways — many of which involve gene editing or regulation...